Introduction {#s1}
============

Neutrophils, also known as polymorphonuclear (PMN) leukocytes, are the most abundant cell type in human blood. They are produced in the bone marrow in large numbers, \~10^11^ cell per day. Under homeostatic conditions, neutrophils enter the circulation, migrate to tissues, where they complete their functions, and finally are eliminated by macrophages, all in the lapse of a day. Neutrophils are important effector cells in the innate arm of the immune system (Mayadas et al., [@B122]). They constantly patrol the organism for signs of microbial infections, and when found, these cells quickly respond to trap and kill the invading pathogens. Three main antimicrobial functions are recognized for neutrophils: phagocytosis, degranulation, and the release of nuclear material in the form of neutrophil extracellular traps (NETs) (Figure [1](#F1){ref-type="fig"}). These functions were considered, until recently, the only purpose of neutrophils. However, current research by investigators in several fields of neutrophil cell biology has revealed that neutrophils possess a much diverse repertoire of functional responses that go beyond the simple killing of microorganisms. Neutrophils respond to multiple signals and respond by producing several cytokines and other inflammatory factors that influence and regulate inflammation and also the immune system (Nauseef and Borregaard, [@B132]; Scapini and Cassatella, [@B153]). Nowadays it is recognized that neutrophils are transcriptionally active complex cells (Ericson et al., [@B50]) that produce cytokines (Tecchio and Cassatella, [@B175]), modulate the activities of neighboring cells and contribute to the resolution of inflammation (Greenlee-Wacker, [@B81]), regulate macrophages for long-term immune responses (Chen et al., [@B25]), actively participate in several diseases including cancer (Uribe-Querol and Rosales, [@B181]; Mishalian et al., [@B128]), and even have a role in innate immune memory (Netea et al., [@B133]).

![Antimicrobial mechanisms of neutrophils. When neutrophils recognize microbial pathogens, they deploy different functions to destroy them. Phagocytosis involves the ingestion of the microorganism into a phagocytic vacuole that upon maturation becomes a phagolysosome. In this new organelle, the microorganism is destroyed by the action of low pH, and degrading enzymes. Neutrophils also degranulate and release to their environment the contents of their granules. When the microorganism is too large to be ingested, neutrophil can also produce extracellular traps (NETs) formed by DNA fibers and proteins from the granules.](fphys-09-00113-g0001){#F1}

The multitude of neutrophil functional responses is induced by transcriptional activation and by changes in expression of surface molecules or activity. These phenotypic changes are usually detected in only a subset of neutrophils, suggesting that great neutrophil heterogeneity exists (Beyrau et al., [@B5]). Neutrophils display different phenotypes from the time they leave the bone marrow and enter the circulation (fresh neutrophils) to the time they disappear from the circulation (aged neutrophils). This shift in phenotype is known as aging, since it takes place within a single day, and results in various neutrophils with distinct properties (Adrover et al., [@B2]). In addition, the microenvironment in different tissues can induce neutrophils to acquire specialized functions. Thus, the fact that neutrophils can display many functional phenotypes further supports the existence of several neutrophil subsets.

Cancer is a particular condition, in which the number of neutrophils in circulation increases, and the phenotype of these cells changes along tumor progression. In advanced cancer, several subpopulations of circulating neutrophils with different characteristics of maturity, tumor cytotoxicity, and immune suppression have been described (Sagiv et al., [@B151]), including the granulocytic myeloid derived suppressor cells (G-MDSC). However, these different cell types are not clearly defined and their existence as bona fide neutrophil subsets or even a complete different cell type is today a controversial topic. For most researchers, it is clear that the differences in plasma membrane proteins and functional responses of neutrophils under diverse settings are strong evidence for the remarkable plasticity of neutrophils. Yet, this neutrophil heterogeneity is not supported by consensus criteria by which to define populations of neutrophils in blood and in tissues. Additionally, the stability of observed phenotypes in these subpopulations is not clear. Are these bona fide neutrophil subsets or just various activating stages displayed in response to local factors?

It is the purpose of this review to highlight the differences in functional responses of neutrophils and other cell types, such as G-MDSC, that may or may not be subpopulations of circulating neutrophils. We present the characteristics of the different neutrophil types, describe their functions, and discuss the possible relations among them.

Neutrophil life cycle {#s2}
=====================

Neutrophils represent about 70% of all leukocytes and more than 10^11^ cells are produced every day in the bone marrow (Dancey et al., [@B33]). From there, neutrophils enter the blood where they circulate until they leave into tissues. Once neutrophils reach the end of their lifespan within tissues, they are cleared mostly by macrophages through the process of phagocytosis (Bratton and Henson, [@B16]). Despite this impressive turnover, the number of neutrophils in circulation remains relatively constant thanks to a fine balance between production and elimination (neutrophil homeostasis; von Vietinghoff and Ley, [@B184]). In addition, neutrophils actively change to be able to perform special functions at different times or places.

Granulopoiesis
--------------

Neutrophils are produced in large numbers in the bone marrow from hematopoietic stem cells (Görgens et al., [@B77]). These cells differentiate into multipotent progenitor (MPP) cells that cannot self-renew themselves. MPPs then transform into lymphoid-primed multipotent progenitors (LMPPs), which differentiate into granulocyte--monocyte progenitors (GMPs). These GMPs, under control of the granulocyte colony-stimulating factor (G-CSF) commit to neutrophil generation by turning into myeloblasts (Figure [2](#F2){ref-type="fig"}). These cells then follow a maturation process that includes the stages of promyelocyte, myelocyte, metamyelocyte, band cell, and finally a mature neutrophil (von Vietinghoff and Ley, [@B184]) (Figure [2](#F2){ref-type="fig"}). During differentiation, the developing neutrophil changes its nucleus from a round shape into a banded and then a lobulated morphology, and also the expression of various receptors. The integrin α4β1 (VLA4) and the CXC chemokine receptor 4 (CXCR4) are downregulated, while CXCR2 and Toll-like receptor 4 (TLR4) are upregulated. The bone marrow stroma cells express vascular cell adhesion molecule 1 (VCAM1), a ligand for VLA4, and the chemokine stromal-derived factor-1/SDF-1 (CXCL12), a ligand for CXCR4, in order to retain the progenitor cells in the bone marrow. Mature neutrophils also contain granules and secretory vesicles that store specific proteins relevant to their functions (Häger et al., [@B86]). These granules are formed at particular differentiation stages. Primary (azurophil) granules are found at the myeloblast to promyelocyte stage. Secondary (specific) granules are detected at myelocyte and metamyelocyte stages. Tertiary (gelatinase) granules are found at the band cell stage. Finally, secretory vesicles are detected only in mature neutrophils (Figure [2](#F2){ref-type="fig"}). These granules store an arsenal of antimicrobial enzymes, including elastase, myeloperoxidase, cathelicidins, defensins, and matrix metalloproteinases, which are used to destroy invading pathogens.

![Granulopoiesis. Neutrophils are produced in the bone marrow. From a self-renewing hematopoietic stem cell (HSC), a multipotent progenitor (MPP) cell is formed. MPPs give rise to lymphoid-primed multipotent progenitors (LPMP), which differentiate into granulocyte-monocyte progenitors (GMP). These GMPs, under control of the granulocyte colony-stimulating factor (G-CSF) commit to neutrophil generation by turning into myeloblasts, which then follow a maturation process that includes the stages of promyelocyte, myelocyte, metamyelocyte, band cell, and finally a mature neutrophil.](fphys-09-00113-g0002){#F2}

Neutrophil exit from the bone marrow
------------------------------------

Once neutrophils mature they can leave the bone marrow into circulation. The release of neutrophils is tightly controlled since only 1 or 2% of all neutrophils in the body are found in the blood under normal homeostatic conditions. Mature neutrophils are kept in the bone marrow through the action of two chemokine receptors, CXCR2 and CXCR4. Osteoblasts and other bone marrow stromal cells produce CXCL12 and keep CXCR4-expressing neutrophils in the bone marrow. G-CSF induces neutrophil exit from the bone marrow by interfering with the CXCR4-CXCL12 interaction (Summers et al., [@B172]). In addition, ligands for CXCR2, such as CXCL1, CXCL2, CXCL5, and CXCL8 (in humans) are expressed by endothelial cells outside the bone marrow when neutrophils need to be mobilized into the blood (Eash et al., [@B46]; Köhler et al., [@B104]). G-CSF prompts the release of neutrophils by inducing upregulation of CXCR2 ligands on megakaryocytes (Köhler et al., [@B104]), reduced expression of CXCL12 by bone marrow stroma cells (Petit et al., [@B140]; Semerad et al., [@B160]), and also reduced expression of CXCR4 on neutrophils themselves (Kim et al., [@B101]).

Outside the bone marrow, neutrophil production is also regulated by a cytokine network that involves interleukin (IL)-23 produced by phagocytes and IL-17 produced by T lymphocytes. In this mechanism, macrophages and also dendritic cells phagocytose apoptotic neutrophils (Gordy et al., [@B76]; Jiao et al., [@B95]) leading to a reduction on IL-23 (Stark et al., [@B170]), which in turn controls expression of IL-17 by T lymphocytes (Gaffen et al., [@B62]). Because, IL-17 promotes granulopoiesis and neutrophil release by up-regulation of G-CSF (von Vietinghoff and Ley, [@B184]), the lower levels of IL-17 then result in reduced expression of G-CSF, and a steady-state release of neutrophils. During inflammation, IL-1 can also stimulate neutrophil production through the IL-17-G-CSF axis (Ueda et al., [@B180]), and neutrophils themselves create a positive loop for neutrophil recruitment. Neutrophils can produce IL-17 (Eskan et al., [@B52]), and attract IL-17-producing T lymphocytes (Th17 cells) (Weaver et al., [@B188]). In turn, Th17 cells recruit more neutrophils (Pelletier et al., [@B137]; Zenobia and Hajishengallis, [@B198]). Recently, it was also found that microbiota can induce neutrophil production by increasing IL-17 production (Deshmukh et al., [@B36]).

Neutrophil trafficking and clearance
------------------------------------

Neutrophils from the blood can be mobilized to sites of infection or inflammation through the process known as the leukocyte adhesion cascade (Ley et al., [@B111]; Chavakis et al., [@B24]). Endothelial cells of blood vessels close to the affected site get activated and express adhesion receptors such as E-, and P-selectins. These receptors bind glycoprotein ligands on neutrophils, causing them to roll on the endothelium. Next, the neutrophil is activated by chemokines, which induce a high affinity state in β2 integrins. Binding of integrins to their ligands such as intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 on endothelial cells causes firm adhesion of the neutrophil. Next the neutrophil transmigrates into peripheral tissues (Hajishengallis and Chavakis, [@B88]). Once neutrophils are in the peripheral tissues, they follow gradients of chemoattractans such as formyl-methionyl-leucyl-phenylalanine (fMLF), and the anaphylatoxin C5a to complete their functions (Kolaczkowska and Kubes, [@B105]).

The constant numbers of neutrophils in the circulation are also controlled by central signals delivered by the sympathetic nervous system. In this case, adrenergic nerves induce the temporal expression of adhesion molecules on endothelial cells, allowing neutrophils to bind the endothelium and leave the circulation (Scheiermann et al., [@B156]). This regulation of neutrophil migration into tissues follows a circadian pattern (Scheiermann et al., [@B155]; see below).

Once in tissues, neutrophils undergo apoptosis and are finally cleared through phagocytosis by resident macrophages and dendritic cells. Senescent neutrophils in blood upregulate expression of CXCR4, which allows them to return to the bone marrow for final clearance (Martin et al., [@B117]). The clearance of apoptotic neutrophils is also important for controlling neutrophil production in the bone marrow (Stark et al., [@B170]). Phagocytosis of apoptotic neutrophil triggers an anti-inflammatory response characterized by a reduction in IL-23 by macrophages. As described above, less IL-23 leads to reduced IL-17 levels and to less G-CSF production, and finally, in consequence to reduced granulopoiesis (Stark et al., [@B170]).

Neutrophil subpopulations in health {#s3}
===================================

The previous description of the neutrophil life cycle gives the idea that these cells are produced in the bone marrow, go to the circulation, migrate to sites of infection or inflammation, execute their antimicrobial functions, and then quietly are cleared by tissue-resident macrophages. This simple view for neutrophils being only pathogen-killing cells, is far from the complex behavior neutrophils actually display. It was already mentioned that in fact neutrophils are transcriptionally active cells with the potential to change the expression of several membrane molecules, and to produce cytokines (Tecchio et al., [@B176]; Tecchio and Cassatella, [@B175]), and consequently neutrophils are capable of performing different cell functions depending on the tissues where they are found (Borregaard, [@B9]; Mayadas et al., [@B122]; Nauseef and Borregaard, [@B132]). Thus, neutrophils do not seem to be a homogeneous population that always behaves the same. In fact, the existence of several subpopulations of neutrophils has been suggested in various conditions of health and disease.

Neutrophil subpopulations in the circulation
--------------------------------------------

In normal conditions, neutrophils remain in circulation for just few hours (the half-life is estimated at 6--12 h) before they leave into tissues (Summers et al., [@B172]). During this time, neutrophils appear to change their phenotype. Looking at neutrophils in circulation of healthy mice every 4 h over the course of a day, it was found that these cells change their morphology and phenotype (Casanova-Acebes et al., [@B22]). Freshly released neutrophils from the bone marrow undergo several changes that accumulate until the cells begin to move from the circulation into the tissues. These changes in neutrophil phenotype from the time they are released from the bone marrow (fresh neutrophils) until they leave the circulation (aged neutrophils) in the absence of inflammation are referred to as aging (Adrover et al., [@B2]). The number of total neutrophils oscillates in a circadian way. Fresh neutrophils are released into the blood when the mice begin their activity phase, and aged neutrophils are cleared at the end of their resting stage (Casanova-Acebes et al., [@B22]).

Previous *in vitro* studies on neutrophil aging indicated that there is a spontaneous upregulation of the receptor CXCR4 in cells that are kept in culture. Freshly isolated blood neutrophils present this increase in CXCR4 expression after only 4 h in culture (Nagase et al., [@B131]). As mentioned before, the chemokine CXCL12 produced by bone marrow stroma cells functions as a retention signal for neutrophils. Thus, re-expression of CXCR4 on neutrophils is thought to encourage "senescent" neutrophils to return to the bone marrow (Martin et al., [@B117]). However, in mice with CXCR4-deficient myeloid cells, no changes in neutrophil clearance were observed (Eash et al., [@B47]), suggesting that other organs besides the bone marrow also contribute to neutrophil clearance (Adrover et al., [@B2]). In addition, neutrophils in culture also downregulate the expression of CXCR2, which has opposite effects to CXCR4 and promotes the release of cells from the bone marrow (Eash et al., [@B46]). Therefore, it seems that these phenotypic changes prepare neutrophils to leave the circulation into tissues.

*In vivo* studies have identified other phenotypic changes in neutrophils. In mice, neutrophils that were forced experimentally to stay longer in the circulation presented lower expression of L-selectin (CD62L), together with a higher expression of CXCR4 (Casanova-Acebes et al., [@B22]). These aged neutrophils appeared in the circulation following circadian oscillations over time. They increased in numbers during the day (when mice are at rest), and disappeared in the evening, when mice begin their active phase (Casanova-Acebes et al., [@B22]). Other molecules are also expressed al higher levels on the cell membrane of these aged neutrophils, including CD11b (α~M~) and CD49d (α4), the alpha subunits for integrins Mac-1 and VLA4, respectively. These integrins are involved in adhesion to activated endothelial cells at sites of inflammation. In contrast, the expression of the molecule CD47, a "don\'t eat me" signal for apoptotic cells (Jaiswal et al., [@B94]), was reduced on the membrane of these neutrophils. This would suggest that aged neutrophils are more easily phagocytosed by macrophages. However, in a more recent study, the expression of CD47 was not reduced (Zhang et al., [@B199]). More recently, the surface expression of other molecules has also been found increased in aged neutrophils. Some of these molecules include TLR4, ICAM-1, CD11c, CD24, and CD45 (Zhang et al., [@B199]) (Figure [3](#F3){ref-type="fig"}). Opposite to this, the mouse neutrophil marker Ly6G was also reduced in aged cells (Zhang et al., [@B199]) (Figure [3](#F3){ref-type="fig"}). Together with the changes in surface expression of these molecules, the cells presented morphological changes. Aged neutrophils are smaller, contain fewer granules, and display a granular multilobullar nucleus (Casanova-Acebes et al., [@B22]; Figure [3](#F3){ref-type="fig"}).

![Phenotype of aged neutrophils. Upon release from the bone marrow, a "fresh" neutrophil (PMN) express the surface molecules CD62L and CXCR4. After several (4--6 h) hours in the circulation neutrophils change the expression of many surface molecules. The new phenotype is described as "aged" neutrophils. These aged neutrophils are then cleared from the blood by migration into tissues or by returning to the bone marrow.](fphys-09-00113-g0003){#F3}

In addition, transcriptomic analysis of aging neutrophils revealed that several signaling pathways are different from those active pathways in fresh neutrophils. Signaling related to cell activation, microbial detection, adhesion, migration, and cell death is altered (Zhang et al., [@B199]). These changes in aged neutrophils are similar to changes in neutrophils at inflammation sites. Thus, it might be that aged neutrophils are in an activated state (Adrover et al., [@B2]). Together these reports suggest that neutrophils spontaneously change their phenotype in circulation, such that different surface molecules may facilitate migration into tissues. At present, it is not known how these differences in receptor expression may control neutrophil clearance into particular tissues, but a similar mechanism to the one controlling neutrophil exit from and return to the bone marrow is likely to be at work. Identifying particular neutrophil phenotypes will certainly help us understand how these cells are directed to various parts of the body.

Neutrophil subpopulations in tissues
------------------------------------

In normal homeostasis, neutrophils are found in many tissues (von Vietinghoff and Ley, [@B184], [@B185]), where they perform specialized functions. For the most part, there is very little knowledge on how neutrophils are directed to the different organs, and the particular functions they perform in each tissue. Evidence suggests that indeed neutrophils display different phenotypes in various organs. For example, in the lung a large number of neutrophils accumulate adhered to the vascular lumen and in the interstitial space. These neutrophils are kept in the tissue by a CXCR4-dependent mechanism (Devi et al., [@B37]). Because aged neutrophils express more CXCR4 it is possible that they preferentially migrate to the lungs (Adrover et al., [@B2]). Similarly, in the spleen many neutrophils are found in the marginal zone, producing cytokines that induce somatic hypermutation and antibody production by marginal B lymphocytes (Puga et al., [@B143]). Also, neutrophils in spleen display the phenotype CD62L^low^ CD11b^hi^ ICAM-1^hi^, and have a tendency to produce NETs (Cerutti et al., [@B23]), similar to aged neutrophils in the circulation (Summers et al., [@B172]; Casanova-Acebes et al., [@B22]).

Another subpopulation of neutrophils has been found to preferentially move into lymph nodes to interact with T lymphocytes, carrying antigens to the lymph nodes and mediate T cell activation (Duffy et al., [@B43]; Hampton and Chtanova, [@B90]). These neutrophils can selectively migrate to the lymph node because they express the CCR7 receptor (Beauvillain et al., [@B3]), as well as the integrin LFA-1 and the chemokine receptor CXCR4. These receptors are also involved in neutrophil trafficking through afferent lymphatics (Gorlino et al., [@B78]).

Yet another subtype of neutrophils in tissues is capable of inducing angiogenesis. These neutrophils display the phenotype CD49d^hi^ CXCR4^hi^ VEGFR1. The latter is the receptor for vascular endothelial growth factor-A (VEGF-A). These neutrophils are efficiently recruited to non-vascularized tissues under hypoxia conditions, and promote angiogenesis (Massena et al., [@B119]). Interestingly, this proangiogenic subset of neutrophils is similar to neutrophils that support tumor vascularization (Jablonska et al., [@B93]; see later).

The examples described above indicate that indeed neutrophils can display great phenotypic and functional heterogeneity, and support the idea that at least some of the neutrophil subtypes may derive from aging neutrophils migrating into tissues.

Migrating neutrophil subpopulations
-----------------------------------

Some neutrophils have been observed to perform reverse transendothelial migration (rTEM) or reverse interstitial migration (rIM), depending on their initial location (Nourshargh et al., [@B134]). Neutrophils doing rTEM have been observed in mice (Woodfin et al., [@B190]), whereas neutrophils doing rIM have been seen only in the transparent zebra fish model (Mathias et al., [@B120]). Neutrophils performing rTEM present the phenotype ICAM-1^hi^ CXCR1^low^, which is different from the phenotype ICAM-1^low^ CXCR1^hi^ of circulatory neutrophils and the phenotype ICAM-1^low^ CXCR1^low^ of neutrophils in tissues (Buckley et al., [@B18]).

Neutrophil subpopulations induced by the microbiota
---------------------------------------------------

Neutrophils can modify their functional responses after being exposed to multiple factors, through the process named neutrophil priming (Downey et al., [@B41]; El-Benna et al., [@B48]). Recent studies in mice suggest that microbial products derived from the microbiota can induce neutrophil diversity. For example, diaminopimelic acid-bearing peptides, which are recognized by the nucleotide---binding oligomerization domain containing 1 (NOD1) receptor, modify the lifespan of neutrophils (Hergott et al., [@B92]) and prime neutrophils for improved antimicrobial function (Clarke et al., [@B28]). In addition, endotoxins from the gut microbiota can enter the blood circulation and influence neutrophil aging (Zhang et al., [@B199]) and also the development of B cell-helper neutrophils in the spleen (Puga et al., [@B143]). Thus, neutrophils can display different phenotypes after priming by the microbiota.

Neutrophil subpopulations in disease {#s4}
====================================

As discussed earlier, it is becoming increasingly apparent that neutrophils are much more than just microbe-killing cells. They can display several phenotypes and perform a wide array of cellular functions. Several subsets of neutrophils are found in tissues under homeostatic conditions. We still have much to learn on how these different neutrophil subtypes are generated and recruited to tissues. In addition, various subsets of neutrophils with distinct properties are also detected in pathological conditions particularly in inflammation and in cancer (Silvestre-Roig et al., [@B162]; Yang et al., [@B195]).

Neutrophil subpopulations in inflammation
-----------------------------------------

Neutrophils are the first cell type recruited to sites of inflammation. From there, they can switch phenotypes and generate various subpopulations with different cell functions. Neutrophils can also interact, directly, or via cytokines and chemokines, with other immune cells to modulate both innate and adaptive immune responses. There is not a complete understanding of these subpopulations of neutrophils, but some clear examples showing that bona fide inflammatory subsets occur are mentioned next.

Upon infection with an antibiotic-resistant *Staphylococcus aureus*, two clear subsets of murine neutrophils can be observed. They differ in cytokine production, macrophage activation potential, expression of TLR, and expression of surface molecules. These subsets were named PMN-1 and PMN-2 (Tsuda et al., [@B179]). PMN-1 cells produce IL-12; classically activate macrophages, express TLR2/TLR4/TLR5/TLR8, and CD49d^hi^ CD11b^low^. In contrast, PMN-2 cells produce IL-10; alternatively activate macrophages, express TLR2/TLR4/TLR7/TLR9, and CD49d^low^ CD11b^hi^ (Tsuda et al., [@B179]). In systemic inflammation condition, another subset of neutrophils is generated with low doses of endotoxin. These cells have a hypersegmented nucleus and display the phenotype CD62^low^ CD11b^hi^ CD11c^hi^, which is similar to the one described for murine aged neutrophils (Casanova-Acebes et al., [@B22]; Zhang et al., [@B199]). Also, they are capable of inhibiting T lymphocytes by direct cell contact involving the integrin Mac1, and by local delivery of reactive oxygen species (ROS) (Pillay et al., [@B141]).

In certain organs such as liver and adipose tissue, few neutrophils are detected in normal homeostatic conditions. However, upon an inflammatory state induced by experimental obesity, neutrophil numbers increase rapidly and a metabolic imbalance is slowly generated (Talukdar et al., [@B174]). First, neutrophils release elastase from azurophilic granules. This enzyme can destroy insulin receptor substrate 1 (IRS1) in adipocytes and hepatocytes, and in consequence induce insulin resistance and lipogenesis (Talukdar et al., [@B174]). Supporting a direct role for this neutrophil subtype in metabolic disorders was the observation that altered levels of elastase or its inhibitor (1-antitrypsin) are associated with metabolic syndrome and the onset of diabetes (Mansuy-Aubert et al., [@B116]).

Neutrophil subpopulations induced by metabolic deregulation
-----------------------------------------------------------

As mentioned before, neutrophil effector functions are markedly enhanced after priming. When certain metabolic functions are altered, neutrophils can be primed to present stronger pro-inflammatory responses.

In hyperglycemia human and mouse neutrophils are primed to undergo NETosis (Wong et al., [@B189]). First, neutrophils in circulation respond to high glucose levels by releasing S100 calcium-binding proteins A8 (S100A8) and S100A9, which interact with the receptor for advanced glycation end products (RAGE), and induce macrophages and GMPs in the bone marrow to secrete G-CSF (Kraakman et al., [@B106]). In consequence, production of neutrophils is enhanced (Xiang et al., [@B192]). These new released neutrophils are primed for ROS production and formation of NETs (Wong et al., [@B189]). Similarly, during hypercholesterolemia, neutrophils showed a primed state characterized by elevated ROS production, increased release of myeloperoxidase (MPO) and increased expression of CD11b (Mazor et al., [@B123]). Together, these reports show that hyperglycemia and hyperlipidemia generate primed, proinflammatory neutrophils that may contribute to diabetes, adipose tissue inflammation, and cardiovascular inflammation.

Neutrophil subpopulations and NET formation
-------------------------------------------

NETosis, the process for producing NETs can be activated by multiple types of microorganisms (Fuchs et al., [@B60]; Yipp et al., [@B196]). Yet, the capacity of neutrophils to undergo NETosis can vary with physiological states, suggesting a neutrophil diversity that could be clinically relevant. In fact, several reports indicate that NETs can influence thrombosis (Fuchs et al., [@B61]) and vascular inflammation (Kessenbrock et al., [@B99]; Chistiakov et al., [@B26]), cancer (Berger-Achituv et al., [@B4]; Garley et al., [@B74]) and autoimmunity (Stephenson et al., [@B171]). As mentioned before some metabolic conditions associated with states of chronic inflammation, can increase neutrophil predisposition to form NETs. Hence, neutrophils from diabetic patients (Wong et al., [@B189]) and from systemic lupus erythematosus (SLE) patients (Garcia-Romo et al., [@B66]; Villanueva et al., [@B183]) have been shown to be more prone to NET formation.

Nowadays NETs have been described as a player of several pathophysiological processes, including vascular diseases, such as atherosclerosis and venous thrombosis (Qi et al., [@B144]; Bonaventura et al., [@B8]), and inflammatory pathologies, such as gout and pancreatitis (Hahn et al., [@B87]).

Atherosclerosis is a cardiovascular disease accompanied by chronic vascular wall inflammation and endothelial cell dysfunction (Gisterå and Hansson, [@B75]). Hyperlipidemia can damage endothelial cells, promoting lipid deposition and plaque formation. This usually characterizes the onset of atherosclerosis. Hyperlipidemia and also hypercholesterolemia induce neutrophilia, which is positively associated with atherosclerotic plaque burden (Drechsler et al., [@B42]). Neutrophils attach themselves to atherosclerotic plaques, primarily through NETs formation, where cholesterol crystals function as danger signals, inducing IL-1β-mediated NETs release from neutrophils. Then, components of NETs, such as cathepsin G and cathelicidin-related antimicrobial peptide (CRAMP), can attract monocytes and macrophages to plaques (Döring et al., [@B39]; Wang et al., [@B186]). NETs can also regulate cytokine production from macrophages in atherosclerosis (Warnatsch et al., [@B187]), and induce endothelial dysfunction directly by activation and damage of endothelial cells (Knight et al., [@B103]). Furthermore, proteinases from NETs contribute to plaque instability (Hansson et al., [@B91]). These reports indicate that NETs directly participate in rupture of atherosclerotic plaques (Döring et al., [@B40]), which triggers platelet aggregation and fibrin deposition at the initial site of atherothrombosis. After plaque rupture, thrombin-activated platelets interact with neutrophils at the injured site inducing more formation of NETs (Stakos et al., [@B169]). Thus, neutrophils and NETs are major contributors to atherothrombosis. Different from arteries, thrombosis in veins is usually initiated by endothelial injury (Di Nisio et al., [@B38]) triggered by alteration in the blood flow or endothelial dysfunction (Xu et al., [@B193]). Subsequently, damaged endothelial cells secrete massive amounts of von Willebrand factor and P-selectin, which adhere to platelets and recruit leukocytes (Etulain et al., [@B53]; Michels et al., [@B126]). Platelets then interact directly with neutrophils and promote the production of NETs (Clark et al., [@B27]). NETs can also stimulate the activation of coagulation cascades (Brill et al., [@B17]) and not only platelet adhesion (Massberg et al., [@B118]), but also erythrocyte adhesion (Fuchs et al., [@B61]). Reciprocally, NETs induce endothelial cell activation through NET-derived proteases, histones, and defensins (Saffarzadeh et al., [@B150]), creating a positive feedback loop for thrombosis. These findings and studies in mice showing an association between the risk of venous thrombosis and high neutrophil counts (Ramacciotti et al., [@B147]), confirm that NETs make a substantial contribution to maintenance of venous thrombi.

Another inflammation process in which NETs play an important role is pancreatitis. Acute pancreatitis is an inflammatory disorder of pancreas for which no specific treatment is available. Important risk factors of acute pancreatitis are formation of gallstones and alcohol abuse (Spanier et al., [@B167]). The most severe cases of the disease are associated with mortality, with acute respiratory distress syndrome being the most frequent cause of death in the early phase of the disease (Pandol et al., [@B135]). Obstruction of the pancreatic duct causes blockage of pancreatic secretion, which is accompanied by disorders in organelle function of pancreatic acinar cells (Gukovskaya et al., [@B82]). These disorders promote co-localization of zymogens-containing vesicles and lysosomes leading to formation of co-localization organelles. In co-localized organelles cathepsin B activates trypsinogen to trypsin (Halangk et al., [@B89]; Van Acker et al., [@B182]), which mediates acinar cell death and thus causing severe inflammation of the pancreas (Lankisch et al., [@B108]; Manohar et al., [@B115]). The destroyed tissue will eventually be replaced by fatty tissue, typical of chronic pancreatitis (Braganza et al., [@B12]), if the original acute pancreatitis is not resolved (Braganza et al., [@B12]). Neutrophils infiltrate the pancreatic parenchyma during this acute inflammatory response (Lankisch et al., [@B108]), and can augment trypsinogen activation via ROS. Both trypsin activation and pancreatic injury were reduced in NADPH oxidase-deficient mice(Gukovskaya et al., [@B83]). In addition, infiltrating neutrophils aggravate inflammation by releasing NETs in the pancreas and at the sites of systemic injury, namely, the lungs (Merza et al., [@B125]). NETs incubated *in vitro* with pancreatic acinar cells led to trypsin activation in these cells, degradation of the NETs by treatment with deoxyribonuclease (DNAse) abolished the trypsin activation, reduced local acinar damage, and systemic inflammation (Merza et al., [@B125]). Furthermore, neutrophils enter the pancreatic ducts and there they form large deposits of NETs, also known as aggregated NETs (aggNETs). AggNETs in turn obstruct secretory flow and thereby perpetuate inflammation (Leppkes et al., [@B110]). Therefore, NETs formed after an initial inflammatory stimulus become the activators of further inflammation in the pancreas.

Contrary to the situations mentioned above, Gout is a disease where NETs appear to have a positive effect. Gout is an acute inflammatory reaction originated from precipitation of uric acid in the form of needle-shaped monosodium urate (MSU) crystals (So and Martinon, [@B164]). Aggregates of MSU crystals known as tophi, induce inflammation in the joints and tissues. Local immune cells such as macrophages and dendritic cells take up the crystals via phagocytosis. The MSU-containing phagosomes then fuse with lysosomes. The low pH in phagolysosomes causes a massive release of sodium and consequently raises intracellular osmolarity, which is balanced by passive water influx through aquaporins. This process dilutes intracellular sodium and potassium concentrations. The low potassium is a trigger for activation of NLRP3 inflammasomes (Schorn et al., [@B158]). Inflammasome activation by MSU crystals has been considered a response to "danger," since damaged cells release urate and ATP into the environment (Busso and So, [@B19]). As a consequence of inflammasome activation, proIL-1β is cleaved to release active IL-1β and other pro-inflammatory cytokines (Kingsbury et al., [@B102]; So and Busso, [@B165]). Cytokine release then leads to a rapid and dramatic recruitment of neutrophils. Recruitment of neutrophils is further mediated by CXCR2, CXCL-8, CXCL-1, CXCL-2, and CXCL-3 (Terkeltaub et al., [@B178]). This neutrophil influx is accompanied by the infamously intense clinical symptoms of inflammation during an acute gout attack (So and Martinon, [@B164]). Due to the intense local inflammation, cytokines produced in large quantities can also enter the circulation, resulting in an acute phase response that can trigger fever and leukocytosis (Maueröder et al., [@B121]). Continuous recruitment of neutrophils to the site of inflammation results in very high neutrophil densities (Shah et al., [@B161]). After the neutrophil concentration in the tissue exceeds a certain threshold, NETs begin to aggregate and build aggNETs in which the MSU crystals are embedded in a mesh of DNA and proteins from neutrophil granules. As such, these aggNETs block MSU crystals and also trap and degrade pro-inflammatory mediators by serine proteases attached to the DNA fibers (Schauer et al., [@B154]). MSU crystal-induced aggNET formation is augmented by release of ATP and lactoferrin from activated neutrophils. The release of ATP during NETs formation is of high importance since extracellular nucleotides initiate anti-inflammatory clearance of dead cells by mononuclear phagocytes (Elliott et al., [@B49]). In addition, lactoferrin on NETs abrogates further recruitment of neutrophils and thus contributes to the anti-inflammatory action of NETs in highly infiltrated tissues (Bournazou et al., [@B10]). Clearly, in this case NETs have a positive anti-inflammatory effect.

The inflammation processes described before show that NETs are much more than a simple anti-microbial tool and they can be produced in very different conditions of neutrophil activation. However, NETs are a double-edged sword. On the one hand, "bad" NETs are involved in stimulating inflammation, as shown in the obstruction of blood vessels and pancreatic ducts. On the other hand "good" NETs are able to contribute to the resolution of inflammation as shown in gout (Hahn et al., [@B87]).

In addition, neutrophils primed by microbiota-derived products can form NETs more easily than neutrophils newly released from the bone marrow (Zhang et al., [@B199]). In contrast, the formation of NETs can be blocked by phagocytosis of small microorganisms via the C-type lectin receptor Dectin-1, which acts as a sensor of microorganism size (Branzk et al., [@B15]). Dectin-1 downregulates the translocation of neutrophil elastase (NE) to the nucleus. This protease promotes NETosis by degrading histones in the nucleus (Branzk et al., [@B15]). Also, neutrophils that phagocytose apoptotic cells, lose their capacity to up-regulate β2 integrins and to respond to activating stimuli that induce NETs formation (Manfredi et al., [@B114]). This could explain in part why in conditions in which phagocytosis of apoptotic cells is compromised, such as SLE and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a state of persistent inflammation is observed. These findings imply that heterogeneity in neutrophil function (for example for NETs formation) is also regulated by physiological signals.

It is evident that infection and inflammation can regulate the appearance of neutrophil phenotypes with unique properties. Unfortunately, nowadays we can only (incompletely) describe the function of these neutrophil subtypes. It would become important to characterize these cells at the level of surface markers, functional responses, and transcriptional profiles in order to understand their role in multiple diseases.

Neutrophil subpopulations in cancer
-----------------------------------

The changes in neutrophil phenotype during cancer are perhaps the most impressive and best studied so far. Neutrophils play important and contradictory roles in cancer development, as reflected by several recent reviews (Sionov et al., [@B163]; Swierczak et al., [@B173]; Uribe-Querol and Rosales, [@B181]; Coffelt et al., [@B30]; Mishalian et al., [@B128]). In tumor-bearing mice, the number of circulating neutrophils increases along with tumor progression. Similarly, in patients with advanced cancer counts of neutrophils in blood are also increased. It is not clear how tumors can induce neutrophilia, but a common mechanism seems to be the production by tumors of cytokines that influence granulopoiesis, including G-CSF (McGary et al., [@B124]), IL-1, and IL-6 (Lechner et al., [@B109]). The presence of elevated numbers of neutrophils in the circulation is associated with poor outcome in several types of cancers (Schmidt et al., [@B157]). In addition, the presence of neutrophils in tumors also seems to be an indicator of poor outcome (Sionov et al., [@B163]). For this reason, the counts of neutrophils in blood in relation to other leukocytes have been suggested as a prognostic value in cancer. Therefore, the neutrophil to lymphocyte ratio (NLR) was introduced as a simple and inexpensive biomarker for many types of cancer (Peng et al., [@B138]; Faria et al., [@B54]). In general, the blood NLR is high in patients with more advanced or aggressive cancers (Guthrie et al., [@B84]), and correlates with poor survival of patients with many solid tumors (Paramanathan et al., [@B136]; Templeton et al., [@B177]). Despite the simplicity for using the NLR, it has not been accepted in many clinical settings. One reason for this is that neutrophilia can be the result of elevated granulopoiesis and as a consequence, it is not always a bad sign for cancer progression. Another reason is that neutrophilia does not correlate with poor clinical outcome in all types of cancer. In gastric cancer, for example a high NLR is indicative of positive prognosis (Caruso et al., [@B21]). This is indicative of the great plasticity neutrophils have. They can directly kill tumor cells and control cancer (Yan et al., [@B194]), but they can also acquire a pro-tumor phenotype and favor cancer (Fridlender and Albelda, [@B57]). Therefore, the exact role of neutrophils within the tumor is a controversial matter (Sionov et al., [@B163]; Uribe-Querol and Rosales, [@B181]).

### Myeloid-derived suppressor cells (MDSC)

In several types of cancer, not only an increase in the number of neutrophils in blood is observed, but also an increase in immature myeloid cells (Brandau et al., [@B13]). These immature cells are at various stages of differentiation, accumulate in the spleen of tumor-bearing animals, and present an immunosuppressive phenotype that supports tumor progression (Nagaraj et al., [@B130]; Raber et al., [@B145]; Keskinov and Shurin, [@B98]). For this reason, they were named myeloid-derived suppressor cells (MDSC) (Peranzoni et al., [@B139]). These MDSC are a heterogeneous mixture of cells that can at least be divided into two subgroups: the granulocytic (G-MDSC) and the monocytic (Mo-MDSC) subgroups (Raber et al., [@B145]). The G-MDSC group resembles neutrophils. Hence, some researchers considerer them to be a *bona fide* phenotype of neutrophils (Pillay et al., [@B142]). However, the relationship among these cells is not clear since immature neutrophils do not have immunosuppressive properties (Solito et al., [@B166]), and neutrophils in the circulation are differentiated cells characterized by a lobulated nucleus (Pillay et al., [@B142]); while MDSCs are cells with clear immature morphology, including band or myelocyte-like nuclei (Pillay et al., [@B142]) (Figures [2](#F2){ref-type="fig"}, [4](#F4){ref-type="fig"}).

![Neutrophil subsets that can be separated through density gradient centrifugation. The bulk of mature (normal) neutrophils (PMN) are denser and separate at the bottom of the density gradient. These cells, named high-density neutrophils present the classical neutrophil morphology with a lobulated nucleus and many granules. In the upper part of the gradient, the less dense peripheral blood mononuclear cells (PBMC) are separated. Among these cells, low-density neutrophils can be found. They comprise immature and mature neutrophils with immunosuppressive properties. The immature population is also called granulocytic myeloid derived suppressor cells (G-MDSC).](fphys-09-00113-g0004){#F4}

Murine neutrophils are defined as CD11b^+^ Ly6G^+^ cells (Daley et al., [@B31]). Murine G-MDSC are CD11b^+^ and Ly6G^+^, thus they are considered neutrophils. In contrast Mo-MDSC express CD11b and Ly6C (Brandau et al., [@B13]; Keskinov and Shurin, [@B98]), making them more monocytic- than neutrophil-like cells. In humans the problem is more complex, since the Ly6G antigen does not exist. Human mature neutrophils are defined by the phenotype CD14^−^ CD15^+^ CD16^+^ CD66b^+^ (Dumitru et al., [@B44]). MDSC share all these markers, making it impossible to differentiate these cells from mature neutrophils. An extended panel of six markers (adding CD11b, CD33, and HLA-DR) was used to evaluate human MDSC (Damuzzo et al., [@B32]). Mo-MDSC were described as CD11b^+^ CD14^+^ CD15^−^ CD33^+^ CD66b^+^ HLA-DR^−/low^; while G-MDSC were described as CD11b^+^ CD14^−^ CD15^+^ CD33^+^ CD66b^+^ HLA-DR^−^ (Brandau et al., [@B13]; Favaloro et al., [@B55]; Keskinov and Shurin, [@B98]). Although, these markers show differences between Mo-MDSC and G-MDSC, they do not allow for clear separation of these cells from neutrophils. At present, it is not possible to distinguish whether MDSC are indeed subpopulations of neutrophils or a separate cell type (Solito et al., [@B166]), but an international effort continues to find better ways for identification of these cells by flow cytometry (Mandruzzato et al., [@B113]).

### Low-density neutrophils (LDNs)

An interesting subpopulation of neutrophils is the so-called low-density neutrophils (LDNs). Traditionally, neutrophils are purified by a Ficoll density gradient (Böyum, [@B11]; García-García et al., [@B65]) where they appear at the bottom of the tube (high-density fraction), separated from mononuclear cells, which are found at the interphase of plasma and Ficoll (low-density fraction) (Figure [4](#F4){ref-type="fig"}). In contrast, LDNs are found in the low-density fraction (Sagiv et al., [@B151], [@B152]) (Figure [4](#F4){ref-type="fig"}). Interestingly, the proportion of LDNs in the low-density fraction increases with tumor growth and progression (Mishalian et al., [@B128]), and includes cells with mature and immature neutrophil morphology (Sagiv et al., [@B151]) (Figure [4](#F4){ref-type="fig"}). These LDNs are a subpopulation of neutrophils with characteristics and functions not well described.

Although, LDNs were first reported in the blood of patients with SLE, rheumatoid arthritis, or rheumatic fever (Hacbarth and Kajdacsy-Balla, [@B85]), they attracted attention only recently because they seem to be associated with cancer (Brandau et al., [@B14]; Sagiv et al., [@B151]). These LDNs have been found in many other pathological conditions including sepsis (Morisaki et al., [@B129]), psoriasis (Lin et al., [@B112]), HIV infection (Cloke et al., [@B29]), asthma (Fu et al., [@B59]), ANCA-associated vasculitis (Grayson et al., [@B79]), and malaria (Rocha et al., [@B148]). In addition, LDNs have been reported in natural pregnancy (Ssemaganda et al., [@B168]). During pregnancy, downregulation of T cell functions is required to ensure materno-fetal tolerance. One way to inhibit T cell function is through the enzyme arginase, which depletes ~L~-arginine, an essential amino acid required for proper expression of the T cell receptor CD3 ζ chain and for T cell proliferation (Rodriguez et al., [@B149]; Raber et al., [@B146]). Arginase activity is significantly increased in the peripheral blood of pregnant women and also in term placentae (Kropf et al., [@B107]). The source for arginase in these tissues was identified as LDNs with the phenotype CD15^+^ CD33^+^ CD66b^+^ CD16^low^ (Ssemaganda et al., [@B168]). This phenotype is suggestive of a activated neutrophil (Fortunati et al., [@B56]), and is similar to the phenotype of G-MDSC (Favaloro et al., [@B55]; Keskinov and Shurin, [@B98]). Thus, situations of chronic inflammation and immunosuppression appear to induce neutrophil diversity. Very little is known about the function of these subpopulations of neutrophils. LDNs from SLE patients were also reported to readily form NETs (Villanueva et al., [@B183]), and because these NETs presented autoantigens, it has been suggested that LDNs in these patients are responsible for sustaining chronic inflammation leading to autoimmunity (Garcia-Romo et al., [@B66]; Khandpur et al., [@B100]). Similarly, it was recently reported that the number of CD66b^+^ LDNs was markedly elevated in peritoneal cavity after abdominal surgery of gastric cancer (Kanamaru et al., [@B96]). These LDNs readily formed NETs that selectively attached cancer cells (Kanamaru et al., [@B96]). These NETs could then assist the clustering and growth of free tumor cells disseminated in the abdomen.

The origin of LDNs remains unclear. Since LDNs are a mixture of cells with segmented or banded nuclei and myelocyte-like cells, one thought is that LDNs are immature neutrophils that are released from the bone marrow during chronic inflammation or immunosuppression (Denny et al., [@B35]; Carmona-Rivera and Kaplan, [@B20]). Another possibility is that these LDNs are activated neutrophils that have undergone degranulation and therefore they have a reduced density (Rocha et al., [@B148]; Deng et al., [@B34]). In mouse models of cancer, these LDNs seem to derive either from immature cells released by the bone marrow (Youn et al., [@B197]) or from normal-density neutrophils (Sagiv et al., [@B151]). It is important to notice that these LDNs are still not properly characterized. The immunosuppressive function of these cells has not been directly determined and the transition of mature (normal density) to LDNs appears to involve an increase in volume rather than degranulation (Sagiv et al., [@B151]). Thus, most likely these LDNs are not activated normal neutrophils. In addition, since SLE patients have chronic inflammation, it is unlikely that their LDNs present immunosuppressive activity. All these possibilities need to be further studied in the future. However, one serious limitation for the characterization of these cells is that there are not specific molecular markers that could distinguish among these possible neutrophils subpopulations.

### Tumor-associated neutrophils (TANs)

The phenotypic changes of circulating neutrophils during tumor progression are also related to infiltration of neutrophils into tumors. Unfortunately, the relationship among immunosuppressive cells (MDSC), LDNs, high-density (normal) neutrophils, and tumor-associated neutrophils (TANs) is just beginning to be elucidated (Mishalian et al., [@B127]; Uribe-Querol and Rosales, [@B181]; Figure [5](#F5){ref-type="fig"}).

![Neutrophils in the circulation display different phenotypes. Mature (normal) neutrophils (PMN) leave the bone marrow and display the classical pro-inflammatory and anti-tumor properties of these cells. It is thought that these PMN can migrate into tumors and display an anti-tumor (N1) phenotype. In tumor-bearing mice, immature neutrophils, such as band cells, also leave the bone marrow into the circulation. These "low-density" neutrophils include granulocytic myeloid derived suppressor cells (G-MDSC) and neutrophils with immunosuppressive properties. These cells can infiltrate tumors and display pro-tumor (N2) phenotype. Under the influence of transforming growth factor-beta (TGF-β, normal PMN can change into "low-density" neutrophils. The exact origin of recruited neutrophils is not known. Also, it is not clear if N1 cells can change into N2 cells and vice versa under the influence of the tumor microenvironment.](fphys-09-00113-g0005){#F5}

Depending on the phenotype displayed by TANs in tumor-bearing mice, they have been classified as N1 or N2 (Fridlender et al., [@B58]). This classification is analogous to antitumor tumor-infiltrating macrophages (M1) or protumor macrophages (M2) (Galdiero et al., [@B63]). Murine N1 TANs are proinflammatory and antitumorigenic. In contrast, N2 TANs are protumorigenic (Fridlender et al., [@B58]). When tumor-bearing mice were treated to inhibit transforming growth factor-beta (TGF-β functions, the CD11b^+^ Ly6G^+^ neutrophils recruited to tumors were hypersegmented, more cytotoxic and more proinflammatory (N1). In contrast, in presence of TGF-β, had a protumor (N2) phenotype. Therefore, it seems that TGF-β within the tumor microenvironment induces a population of TANs with a protumor activity (Fridlender et al., [@B58]). This means that TANs can display an antitumor (N1) phenotype or a pro-tumor (N2) phenotype depending on the tumor microenvironment (Sionov et al., [@B163]). In addition, in tumor-bearing animals the LDNs increased progressively in circulation, were not cytotoxic, and had reduced expression of cytokines (Sagiv et al., [@B151]). The authors proposed that these immunosuppressive LDNs (G-MDSC) are the source of N2 TANs (Sagiv et al., [@B151]) (Figure [5](#F5){ref-type="fig"}). This is consistent with the idea that some of the LDNs are indeed immature neutrophils (Sagiv et al., [@B151]). Also, in the same murine model mature neutrophils were capable of becoming LDNs upon treatment with TGF-β (Sagiv et al., [@B151]). This has been interpreted as normal mature neutrophils having the capacity to infiltrate tumors and being cytotoxic, but under the influence of TGF-β, being able to change into N2 cells (Mishalian et al., [@B127]) (Figure [5](#F5){ref-type="fig"}). Although attractive, this hypothesis requires further evidence to be validated, since TGF-β was able to induce this change in tumor-bearing mice, but it had no effect on tumor-free mice (Sagiv et al., [@B151]).

It is important to emphasize here that the paradigm of N1 and N2 TANs has been described only in murine models of cancer, and that the nature and function of TANs in the tumor microenvironment remains largely unknown, particularly with human tumors. There are only two reports on isolation of human TANs, but they describe controversial data on their immunosuppression capacity. In one report, TANs were isolated from digested human lung tumors (Eruslanov et al., [@B51]). These TANs had an activated phenotype (CD62L^low^ CD54^hi^) and produced l proinflammatory cytokines. In consequence, these TANs stimulated T cell proliferation and interferon gamma (IFN-γ) production (Eruslanov et al., [@B51]). In another report, TANs were isolated from a colorectal tumor and found to present a typical neutrophil morphology. These TANs had the phenotype CD45^+^ Lin^−^ HLADR^−^ CD11b^+^ CD33^+^ CD66b^+^, and were classified as G-MDSC (Wu et al., [@B191]). These TANs secreted arginase 1 (ARG1) and ROS, and inhibited proliferation of activated autologous T cells and IFN-γ production (Wu et al., [@B191]). Together these reports suggest that neutrophils are present in three subpopulations in cancer: normal high-density neutrophils, immature LDNs (G-MDSC), and large mature LDNs (Figure [5](#F5){ref-type="fig"}). Early TANs (N1) are not immunosuppressive, but rather stimulate T cell responses (Eruslanov et al., [@B51]). Latter, the cells acquire an N2 phenotype and become immunosuppressive (Wu et al., [@B191]) (Figure [5](#F5){ref-type="fig"}).

### Immunogenic cell death

Recently, another important role of neutrophils in anticancer therapy has been described. Immunogenic cell death can stimulate neutrophils to utilize cytotoxicity against residual live cancer cells after therapy. The concept of immunosurveillance explains how only the most immunoevasive or highly mutagenic neoplastic cells are able to generate clinically relevant tumors (Dunn et al., [@B45]; Schreiber et al., [@B159]). Yet, the immune system is capable of recognizing altered-self molecules in damaged cells through endogenously derived danger signals or alarmins (Bianchi, [@B7]; Garg et al., [@B70]). As a consequence of cell death, alarmins, collectively referred to as "damage-associated molecular patterns" (DAMPs), enhance sensing of dying cells by innate immune cells (Zitvogel et al., [@B200]; Garg et al., [@B69]). Release of DAMPs can either be achieved in an unregulated fashion by necrosis (Aaes et al., [@B1]) or in a regulated fashion by immunogenic cell death, also called immunogenic apoptosis (Kepp et al., [@B97]; Garg et al., [@B68]). Anti-cancer therapy-induced cancer cell death can be subdivided into three distinct types i.e., tolerogenic cell death, inflammatory cell death, and immunogenic cell death. The details of these types of cell death are beyond the scope of the present publication, but the reader is directed to some excellent recent reviews (Green et al., [@B80]; Garg et al., [@B72]; Garg and Agostinis, [@B67]). Briefly, immunogenic cell death is characterized by a defined discharge of DAMPs, type I interferon response, and the production of pathogen response-like chemokines (CXCL1, CCL2, and CXCL10) (Garg et al., [@B73]) that together raise the immunogenic potential of dying cancer cells.

Through immunogenic cell death, after some types of anti-cancer therapy (Galluzzi et al., [@B64]; Bezu et al., [@B6]; Garg et al., [@B71]), a damaged cancer cell produces specific inflammatory chemokines to recruit neutrophils as first innate immune cells (Kolaczkowska and Kubes, [@B105]; Garg et al., [@B73]). The damaged cancer cells also express two important "eat me" signals on their membranes, namely, phosphatidylserine, and calreticulin. These signals trigger neutrophil phagocytosis of cancer cells and pro-inflammatory stimulation, leading to a change in neutrophil phenotype (Garg et al., [@B73]). Neutrophils expressed a mature phenotype characterized by expression of CD86^hi^ MHC-II^hi^, and an activated phenotype characterized by IL-6^hi^ IL-1β^hi^ IL-10^low^ expression (Garg et al., [@B73]). As a result, neutrophils stimulated by immunogenic cell death showed cytotoxicity against residual live cancer cells (Garg et al., [@B73]). Thus, neutrophils interacting with immunogenic apoptotic cells gain a pro-inflammatory profile, culminating into neutrophil dependent cytotoxicity against residual cancer cells.

Conclusion {#s5}
==========

There is a lot of excitement around the many "new" neutrophil functions just discovered recently. The realization that neutrophils do in fact perform many more functions than just antimicrobial responses, and the fact that neutrophils with different phenotypes have been reported in various tissues and pathological conditions, suggest that indeed different neutrophils exist. However, in most reports the evidence is circumstantial and we are in need for solid experimental proof that the cells described are in fact novel neutrophil subsets. What we have learned for sure so far is that in various pathological conditions, particularly cancer, distinct populations of mature and immature neutrophils are found in circulation. After gradient density centrifugation of blood, the mature high-density (or more properly normal-density) neutrophils mostly represent cells with a pro-inflammatory phenotype, while the LDNs are comprised of immature neutrophils and "activated" mature neutrophils. These cells in turn may migrate to tumors and become, at least in mice, N1 and N2 TANs (Figure [5](#F5){ref-type="fig"}). However, we have to highlight that the actual cell type responsible for the immunosuppressive properties of MDSC remains a mystery.

Many questions remain open, but at least two topics seem to be relevant at the moment. One important topic that needs to be addressed is whether mature neutrophils in circulation can be reprogrammed by external stimuli, or whether defined phenotypes are programmed in the bone marrow and neutrophils exit with a particular phenotypic signature. Evidence suggests that neutrophils are very plastic cells and in consequence the various subtypes described seem to be acquired in the tissues. However, these possibilities need to be formally tested. Another relevant topic is that the many functions described have not been assigned to particular phenotypes of neutrophils. This remains a complex issue, as there are currently no appropriate molecular markers to readily identify these different neutrophil subpopulations. This confusing scenario is the fuel for new and even more exciting research. We expect to learn new tricks from our favorite cell type in the near future.
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